Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2023-01-24 00:00:00 ET · period of report 2023-01-20 · accession 0001737287-23-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-24 | 2023-01-20 | ALLO | Roberts Zachary | EVP of R, D | A - Grant | $0.00 | +251.9K | 251.9K | New | $0 |
| D | 2023-01-24 | 2023-01-20 | ALLO | Roberts Zachary | EVP of R, D | A - Grant | $0.00 | +873.0K | 873.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-20 | A | A | 251,908 | $0.00 | 251,908 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-01-20 | A | A | 873,015 | $0.00 | 873,015 | D | $6.55 · — to 2033-01-20 | 873,015 Common Stock | (F1) 25% of the shares subject to the stock option shall vest on January 03, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |